Loading organizations...
ODAIA Intelligence is a technology company.
ODAIA Intelligence provides an AI-powered commercial intelligence platform for the pharmaceutical industry. Its core products, ODAIA Field and ODAIA Field Coach, integrate customer data, behavioral science, and AI to deliver predictive analytics and actionable insights. The platform optimizes Healthcare Professional (HCP) engagement, dynamic segmentation, and omnichannel execution, helping pharma identify new prescription opportunities and boost sales.
Founded in 2018, ODAIA emerged from the University of Toronto, led by CEO Philip Poulidis and co-founder Helen Kontozopoulos, an adjunct professor. Their core insight involved applying advanced AI and data science to improve commercial engagement strategies in life sciences, addressing market inefficiencies.
The platform assists biopharma companies, from large to mid-sized organizations, empowering sales representatives and managers to engage more effectively with HCPs. ODAIA’s vision is to transform life sciences commercial engagement by offering a deep understanding of HCPs and their patient decisions, fostering intelligent, personalized interactions for better health outcomes.
ODAIA Intelligence has raised $39.0M across 3 funding rounds.
ODAIA Intelligence has raised $39.0M in total across 3 funding rounds.
ODAIA Intelligence is a Toronto‑born technology company that builds AI‑powered commercial intelligence and predictive analytics platforms for life‑sciences commercial teams, aiming to optimize how pharmaceutical and biotech companies engage healthcare professionals and manage patient journeys[1][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick takeaway: ODAIA Intelligence is a research‑rooted AI‑SaaS company focused on bringing explainable, predictive customer‑journey intelligence to pharmaceutical commercial teams, addressing a pressing need to modernize targeting and engagement with data‑driven workflows—momentum appears real, and future growth will depend on broader adoption across pharma and successful operational integration with existing commercial systems[1][3][4].
ODAIA Intelligence has raised $39.0M in total across 3 funding rounds.
ODAIA Intelligence's investors include Charles Conn, Megan Kelly, BDC Capital, Flint Capital, Graphite Ventures, StandUp Ventures, Wittington Ventures, Innospark Ventures, Paladin Capital Group, Sean Cunningham, Michael Cloutier.
ODAIA Intelligence has raised $39.0M across 3 funding rounds. Most recently, it raised $25.0M ODAIA - Series B in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 2, 2023 | $25.0M ODAIA - Series B | Charles Conn, Megan Kelly | BDC Capital, Flint Capital, Graphite Ventures, StandUp Ventures, Wittington Ventures |
| Dec 1, 2021 | $10.0M Series A | Innospark Ventures, Paladin Capital Group, Sean Cunningham | |
| May 18, 2021 | $4.0M ODAIA - Seed | Michael Cloutier |